AAM Launches #DoesntAddUp Ad Campaign to Bring Down Prescription Drug Costs for Patients in the U.S.
Patient Cost Rising While Generic Prices Fall Doesn’t Add Up WASHINGTON DC (October 23, 2019) – The Association for Accessible Medicines (AAM) today launched its seven-figure #DoesntAddUp advertising campaign to raise awareness among policymakers of the generic and biosimilar industry’s significant market access challenges and promote potential solutions to ensure patients can access their medicines. […]
2019 Generic Drug and Biosimilars Access & Savings in the U.S. Report
Overview To view the latest data, view 2020 Access & Savings Report 2019 Generic Drug and Biosimilars Access and Savings in the U.S. The 11th annual edition of AAM’s Savings and Access Report quantifies how much money American patients and our health care system are saving because of generic and biosimilar alternatives to brand-name prescription […]
AAM Statement on Generic and Biosimilar Drugmaker Inability to Acquire Samples
“Patients, payers and the government all lose when some brand manufacturers misuse FDA safety protocols to withhold samples from generic and biosimilar drugmakers, which delays market competition and keeps drug prices artificially high. Sample medicines are needed by the generic and biosimilar companies to conduct product development and bioequivalence studies necessary for FDA approval. The […]
AAM White Paper: Ensuring the Future of Accessible Medicines in the U.S.
Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for […]
How Generic Drug Makers Are Responding to Price-Fixing Lawsuit
WASHINGTON, DC (May 16, 2019) — AAM President and CEO Chester “Chip” Davis, Jr. appeared on PBS Newshour last night to respond to allegations by Connecticut Attorney General William Tong, who was also a guest. Generic medicines are 90 percent of all prescriptions filled and are available for 22 percent of total cost to the […]
The 11th Annual Edition of AAM Access & Savings Report Finds Generic Savings Totaled $293 Billion in 2018
WASHINGTON, DC (May 13, 2019) — The Association for Accessible Medicines (AAM) has released details of its 2019 Access & Savings Report, with key findings that underscore the importance of generics and biosimilars to American patients. According to the forthcoming report, the U.S. health care system has saved $2 trillion in the last decade due […]
Response to 60 Minutes May 12, 2019: AAM Statement on the Importance of Competition to Promote Accessibility and Affordability of Medicines
WASHINGTON, DC (May 12, 2019) — The Association for Accessible Medicines (AAM) and its member companies are committed to supporting policies that promote competition and help speed the availability of generic and biosimilar medicines to patients. Today’s generic drug industry is characterized by intense competition. As a result, pricing data from the last three years […]
2016 Savings and Access Report
Generic Medicines Drive Savings, Not Costs The generic pharmaceutical industry plays an important role in the health system and generic drug manufacturers are true drivers of health system value — generating savings and enhancing access for patients, public programs, taxpayers, employers and others who rely on more affordable medicines. The 8th annual 2016 Generic Drug […]
AAM Statement: 2019 Energy and Commerce Health Subcommittee Markup
WASHINGTON, DC (March 27, 2019) – The generic and biosimilar industry greatly appreciates the efforts of the Energy and Commerce Health Subcommittee to pass the CREATES Act and advance this bipartisan market-based solution to end abuse of FDA’s safety programs. Today’s markup, unfortunately, represents one step forward and two steps back for patients who want competition […]
HHS Proposal Will Help America’s Patients Realize the Full Value of Their Generics and Biosimilars
America’s patients continue to cite high prescription drug costs as a major issue, and the Trump administration has responded with a series of proposals to reduce out-of-pocket costs for patients and overall spending on high-priced brand drugs. While its recent, bold proposal to ban brand drug manufacturers from offering rebates for preferred formulary access for […]
Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631
WASHINGTON, DC (February 19, 2019) – Today’s decision is a victory for patients who depend on a strong national market for generic and biosimilar medicines. Maryland’s law would have allowed one state to dictate prices in the competitive national market for generic medicines that saved patients and taxpayers $265 billion in 2017. The Association for […]
AAM Statement on Trump Administration’s Proposal to Lower Drug Costs by Targeting Backdoor Rebates
WASHINGTON DC (February 1, 2019) – “AAM applauds the Administration’s efforts to reduce high brand drug costs for patients. Too often, brand drug companies are using rebate traps to block patient access to more affordable generic or biosimilar medicines. We look forward to reviewing the proposal and working with the Administration to ensure that America’s […]
